🇺🇸 FDA
Patent

US 9737513

Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

granted A61KA61K31/4245A61K47/02

Quick answer

US patent 9737513 (Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy) held by PTC THERAPEUTICS, INC. expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/4245, A61K47/02, A61K47/10, A61K47/12